Literature DB >> 32273475

Identification of biallelic germline variants of SRP68 in a sporadic case with severe congenital neutropenia.

Barbara Schmaltz-Panneau1, Anne Pagnier2, Séverine Clauin3, Julien Buratti3, Caroline Marty1, Odile Fenneteau4, Klaus Dieterich5, Blandine Beaupain6, Jean Donadieu7, Isabelle Plo1, Christine Bellanné-Chantelot8.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32273475      PMCID: PMC8018125          DOI: 10.3324/haematol.2020.247825

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
Congenital neutropenia (CN) are a heterogeneous group of very rare diseases characterized by profound and chronic neutropenia possibly associated with comorbidities. [1] Variants in about 25 genes implicating distinct pathophysiological pathways have been identified in CN.[1] Recently, co-translational targeting of nascent secretory and membrane proteins to the endoplasmic reticulum (ER) mediated by the signal recognition particle (SRP) complex has been implicated in the pathogenesis of both CN and Shwachman-Diamond-like syndrome.[2,3] In humans, the SRP complex is composed of six proteins (SRP9, SRP14, SRP19, SRP54, SRP68, and SRP72) assembled on a 7S RNA molecule.[4] The SRP54 protein with its GTPase activity constitutes the key element of this complex and regulates the entire physiological process.[5] We recently reported germline SRP54 variants in a large number of sporadic and familial cases with autosomal dominant CN.[3] Apart from SRP54, germline heterozygous variants of SRP72 have been described in a few cases with aplastic anemia and myelodysplasia.[6,7] Here, we report a sporadic case of severe CN associated with biallelic pathogenic variants of SRP68, implicating for the first time the SRP68 protein in the pathogenesis of CN. Specifically, we investigated the functional consequences of SRP68 defect on granulopoiesis and on ER homeostasis (see the Online Supplementary Appendix). The patient is a Caucasian boy referred for an anal abscess at 6 weeks of age. Blood counts showed severe neutropenia (white blood cells 6.1x109/L, neutrophils 0.2x109/L), elevated monocyte count (1.7x109/L), anemia (hemoglobin 7.5 g/dL) associated with iron deficiency and moderate thrombocytopenia (platelets 149x109/L). Serial blood counts (n=41) confirmed the persistent and profound neutropenia (0.200x109/L [range: 0-1.800]). The bone marrow examination showed a maturation arrest at the promyelocytic stage and major features of dysgranulopoiesis. Promyelocytes displayed numerous condensed granulations, abnormal nuclei, clumped chromatin and the absence of cytoplasmic vacuoles; the remaining neutrophils were highly dystrophic (Figure 1A). In the first year of life, neutropenia was associated with profound anemia and thrombocytopenia which recovered later. The level of hemoglobin and the platelet count were respectively 8.7 g/dL [range, 5.5-11.3] and 132x109/L [range, 43-318]). From diagnosis to the last follow-up at the age of 5 years, he had a prophylactic antibiotherapy and was treated with granulocyte colony-stimulating factor (5 to 10 mg/kg/day). With this treatment and despite the persistent severe neutropenia, the patient has not presented severe bacterial infections. There was no familial medical history. After excluding the genes classically involved in CN by targeted high throughput sequencing, we performed whole exome sequencing (WES) on a triobased approach (Online Supplementary Appendix). WES diagnosed an intronic homozygous point substitution affecting the splice donor site of exon 1 (c.184+2T>C) of the SRP68 gene. This variant was detected at a heterozygous state in his mother and was absent in his father suggesting the presence in trans of a large deletion (Online Supplementary Table S1). Sanger sequencing and quantitative polymerase chain reaction (PCR) confirmed the splice site variant and the deletion of exon 1 of SRP68 (Figure 1B-C; Online Supplementary Table S2). This latter was inherited from his father confirming the compound heterozygous SRP68 genotype (c.184+2T>C) (exon 1 deletion) of the patient.
Figure 1.

A sporadic case with severe congenital neutropenia and loss-of-function variants of (A) Cytology analysis after May Grunwald-Giemsa staining of patient’s bone marrow. Pictures represent granulocytic precursors (left) and neutrophils (right) (original magnification x100). (B) Sanger sequencing confirmation of the splice site variant c.184+2T>C located in intron 1 of SRP68. F: forward strand; R: reverse strand. (C) Confirmation of the deletion of exon 1 of SRP68 by quantitative polymerase chain reaction (PCR) using SYBR-Green. (D) Predicted alternate cryptic splice site located 37 bp upstream of the splice donor site shown on SRP68 sequence and confirmed by RT-PCR using RNA extracted from fibroblasts and Sanger sequencing of the shorter product (176 bp). (E) Expression level of SRP68 protein in fibroblasts evaluated by western blot analysis

A sporadic case with severe congenital neutropenia and loss-of-function variants of (A) Cytology analysis after May Grunwald-Giemsa staining of patient’s bone marrow. Pictures represent granulocytic precursors (left) and neutrophils (right) (original magnification x100). (B) Sanger sequencing confirmation of the splice site variant c.184+2T>C located in intron 1 of SRP68. F: forward strand; R: reverse strand. (C) Confirmation of the deletion of exon 1 of SRP68 by quantitative polymerase chain reaction (PCR) using SYBR-Green. (D) Predicted alternate cryptic splice site located 37 bp upstream of the splice donor site shown on SRP68 sequence and confirmed by RT-PCR using RNA extracted from fibroblasts and Sanger sequencing of the shorter product (176 bp). (E) Expression level of SRP68 protein in fibroblasts evaluated by western blot analysis CD34+ cells from the patient and the control donor were purified from blood and cultured for 12 days in serum freemedium with stem cell factor, interleukin 3 and granulocyte colony-stimulating factor. Sorted granulocytic cells CD33+15+11b– and CD33+15+11b+ were sorted on day 12. Expression levels were determined by quantitative everse transcription polymerase chain reaction related to PPIA and HPRT on day 12. (A) Expression level of SRP68 (n=1 in triplicate; mean±standard deviation [SD]). (B) Fold increase in cell proliferation during granulocytic differentiation (n=2; mean±SD). (C) Expression level of ATF4, CHOP and ratio spliced/unspliced XBP1 (n=1 in triplicate; mean±SD). (D) Expression level of P21, BAX, MDM2 and NOXA1 (n=1 in triplicate; mean±SD). In order to determine the consequences of the intronic SRP68 variant on splicing, we performed reverse transcription PCR (RT-PCR) using primary fibroblasts from the patient, his parents, and a control donor. Agarose gel electrophoresis indicated that the patient and his mother harbor both the expected 213 bp fragment and a shorter product (176 bp). Sequencing of this fragment revealed the use of a predicted cryptic splice donor site located 37 bases upstream (c.147) and resulting in the premature truncation of the mutated protein (Ala50Phefs*52) (Figure 1D). By western blot analysis, we found a drastic decrease of SRP68 protein expression in fibroblasts of the patient compared to his parents (Figure 1E) demonstrating the loss-of-function effect of the SRP68 defects. Nevertheless, we observed a residual protein expression in the patient that may be due to a partial splicing defect as suggested by the semi-quantitative analysis of SRP68 transcripts in the mother (ratio 65%/35% for both 213 bp/176 bp fragments, Figure 1D). This finding was also consistent with the SRP68 transcript expression level determined from patient’s granulocytic cells. The residual expression of SRP68 could be explained by the specific post-transcriptional splicing mechanism related to GT>GC variants affecting the canonical 5’ donor splice site as identified in our patient (c.184+2T>C). In fact, 5′ splice site GT>GC variants may retain their ability to generate normal transcripts and be associated with a milder than expected clinical phenotype.[8] SRP68 functions only as a heterodimeric structure with the SRP72 protein.[9] We could speculate that null SRP68 variants would be lethal on the basis of what was recently shown in Srp72-/- mice.[10] We purified CD34+ progenitor cells from peripheral blood and cultured them in serum-free medium supplemented with stem cell factor (25 ng/mL), interleukin 3 (10 ng/mL) and granulocyte colony-stimulating factor (20 ng/mL) for 12 days. The level of SRP68 expression on day 12 was reduced to 68% in immature CD33+CD15+CD11b- cells and to 39% in the more mature CD33+CD15+CD11b+ cells of the patient compared with control cells (Figure 2A). We also analyzed the consequences of SRP68 defect on granulocyte proliferation. In the same experimental conditions, we cultured CD34+ cells purified from blood samples and observed nearly six-times less granulocytic cell proliferation in the patient compared to CD34+ cells from healthy control (Figure 2B).
Figure 2.

CD34+ cells from the patient and the control donor were purified from blood and cultured for 12 days in serum freemedium with stem cell factor, interleukin 3 and granulocyte colony-stimulating factor. Sorted granulocytic cells CD33+15+11b– and CD33+15+11b+ were sorted on day 12. Expression levels were determined by quantitative everse transcription polymerase chain reaction related to PPIA and HPRT on day 12. (A) Expression level of SRP68 (n=1 in triplicate; mean±standard deviation [SD]). (B) Fold increase in cell proliferation during granulocytic differentiation (n=2; mean±SD). (C) Expression level of ATF4, CHOP and ratio spliced/unspliced XBP1 (n=1 in triplicate; mean±SD). (D) Expression level of P21, BAX, MDM2 and NOXA1 (n=1 in triplicate; mean±SD).

These results highlight the major role of the SRP complex during granulocytic differentiation. This physiological process requires the production and maturation of a huge number of granule proteins.[11] This context explains why granulocytic precursors and neutrophils are highly sensitive to alterations of protein synthesis, protein transport into ER/Golgi and ER protein misfolding. A defective co-translational targeting of nascent proteins may either affect the level of ER resident proteins as chaperones and glycosylases or lead to incorrectly translocated proteins essential for granulocytic precursor maturation as the neutrophil elastase ELANE.[12] Both hypotheses will result in ER stress, activation of the unfolded protein response (UPR) and finally, to cycle cell arrest, senescence and/or death by apoptosis or necrosis of granulocytic cells. In mammals, the SRP68/SRP72 heterodimer plays an essential role in the recognition of the signal peptide of nascent proteins and in their translocation through the SRP receptor located at the ER membrane.[13] As we previously showed that SRP54 variants induce an ER stress and activate the UPR pathway, we investigated several markers of UPR activation (ATF4, CHOP and spliced XBP1).[3] Using in vitro sorted granulocytic cells, we found a significant increase in spliced XBP1 expression level in both immature and mature granulocytic cells of the patient in comparison with control cells pointing out the specific activation of the IRE1 ER stress sensor of the UPR signaling (Figure 2C). [14] In contrast to SRP54, no activation of the PERK pathway, another distinct ER sensor, was observed by analyzing ATF4 and CHOP UPR-target genes.[14] Under ER stress conditions, the induction of UPR leads to enhanced apoptosis reducing the number of granulocytic precursors and neutrophils. In most CN, including SRP54-related CN, apoptosis seems to be dependent on p53 pathway activation.[3] We analyzed, by quantitative RT-PCR, the expression level of several P53 target genes (BAX, NOXA1, P21 and MDM2) in sorted granulocytic cells (Figure 2D). The patient displayed a higher expression level of P53 target genes than in control and the activation was more pronounced in the more mature granulocytic CD33+CD15+CD11b+ cells. However, we could not definitively exclude P53-independent pathways that also lead to cell cycle arrest and apoptosis.[15] Of note, P53-independent nucleolar stress has been reported in animal models of bone marrow failure syndromes caused by impaired ribosomal biogenesis and function.[15] Besides the profound neutropenia, this patient presented transient severe anemia and thrombocytopenia as also reported in patients harboring SRP54 and SRP72 defects.[3,6] We could hypothesize that an aberrant SRP complex, regardless of the implicated defective SRP protein, may have consequences on the targeting of proteins essential for hematopoietic stem cells or erythroid, megakaryocytic and granuloytic progenitor/precursors. Further studies are needed to characterize the mechanisms leading to impaired differentiation of hematopoietic lineages and to identify the protein partners of the SRP complex. In conclusion, we have identified a novel genetic entity of CN affecting another protein of the SRP complex underlying the major implication of the universally conserved co-translational targeting machinery of proteins in the pathogenesis of CN. These first observations show that loss-of-function SRP58 variants trigger an ER stress resulting in an increased P53-dependent apoptosis of granulocytic precursors and neutrophils.
  15 in total

1.  Heterodimeric GTPase core of the SRP targeting complex.

Authors:  Pamela J Focia; Irina V Shepotinovskaya; James A Seidler; Douglas M Freymann
Journal:  Science       Date:  2004-01-16       Impact factor: 47.728

2.  First estimate of the scale of canonical 5' splice site GT>GC variants capable of generating wild-type transcripts.

Authors:  Jin-Huan Lin; Xin-Ying Tang; Arnaud Boulling; Wen-Bin Zou; Emmanuelle Masson; Yann Fichou; Loann Raud; Marlène Le Tertre; Shun-Jiang Deng; Isabelle Berlivet; Chandran Ka; Matthew Mort; Matthew Hayden; Raphaël Leman; Claude Houdayer; Gerald Le Gac; David N Cooper; Zhao-Shen Li; Claude Férec; Zhuan Liao; Jian-Min Chen
Journal:  Hum Mutat       Date:  2019-06-24       Impact factor: 4.878

Review 3.  Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history.

Authors:  Jean Donadieu; Blandine Beaupain; Odile Fenneteau; Christine Bellanné-Chantelot
Journal:  Br J Haematol       Date:  2017-09-06       Impact factor: 6.998

4.  Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome.

Authors:  Christine Bellanné-Chantelot; Barbara Schmaltz-Panneau; Caroline Marty; Odile Fenneteau; Isabelle Callebaut; Séverine Clauin; Aurélie Docet; Gandhi-Laurent Damaj; Thierry Leblanc; Isabelle Pellier; Cécile Stoven; Sylvie Souquere; Iléana Antony-Debré; Blandine Beaupain; Nathalie Aladjidi; Vincent Barlogis; Frédéric Bauduer; Philippe Bensaid; Odile Boespflug-Tanguy; Claire Berger; Yves Bertrand; Liana Carausu; Claire Fieschi; Claire Galambrun; Aline Schmidt; Hubert Journel; Françoise Mazingue; Brigitte Nelken; Thuan Chong Quah; Eric Oksenhendler; Marie Ouachée; Marlène Pasquet; Véronique Saada; Felipe Suarez; Gérard Pierron; William Vainchenker; Isabelle Plo; Jean Donadieu
Journal:  Blood       Date:  2018-06-18       Impact factor: 22.113

5.  Mutations of the ELA2 gene found in patients with severe congenital neutropenia induce the unfolded protein response and cellular apoptosis.

Authors:  David S Grenda; Mark Murakami; Jhuma Ghatak; Jun Xia; Laurence A Boxer; David Dale; Mary C Dinauer; Daniel C Link
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

6.  Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features.

Authors:  Raphael Carapito; Martina Konantz; Catherine Paillard; Zhichao Miao; Angélique Pichot; Magalie S Leduc; Yaping Yang; Katie L Bergstrom; Donald H Mahoney; Deborah L Shardy; Ghada Alsaleh; Lydie Naegely; Aline Kolmer; Nicodème Paul; Antoine Hanauer; Véronique Rolli; Joëlle S Müller; Elisa Alghisi; Loïc Sauteur; Cécile Macquin; Aurore Morlon; Consuelo Sebastia Sancho; Patrizia Amati-Bonneau; Vincent Procaccio; Anne-Laure Mosca-Boidron; Nathalie Marle; Naël Osmani; Olivier Lefebvre; Jacky G Goetz; Sule Unal; Nurten A Akarsu; Mirjana Radosavljevic; Marie-Pierre Chenard; Fanny Rialland; Audrey Grain; Marie-Christine Béné; Marion Eveillard; Marie Vincent; Julien Guy; Laurence Faivre; Christel Thauvin-Robinet; Julien Thevenon; Kasiani Myers; Mark D Fleming; Akiko Shimamura; Elodie Bottollier-Lemallaz; Eric Westhof; Claudia Lengerke; Bertrand Isidor; Seiamak Bahram
Journal:  J Clin Invest       Date:  2017-10-03       Impact factor: 14.808

Review 7.  Dynamics of co-translational protein targeting.

Authors:  Margaret M Elvekrog; Peter Walter
Journal:  Curr Opin Chem Biol       Date:  2015-10-30       Impact factor: 8.822

8.  Human apo-SRP72 and SRP68/72 complex structures reveal the molecular basis of protein translocation.

Authors:  Yina Gao; Qi Zhang; Yue Lang; Yang Liu; Xiaofei Dong; Zhenhang Chen; Wenli Tian; Jun Tang; Wei Wu; Yufeng Tong; Zhongzhou Chen
Journal:  J Mol Cell Biol       Date:  2017-06-01       Impact factor: 6.216

Review 9.  Nucleolar stress with and without p53.

Authors:  Allison James; Yubo Wang; Himanshu Raje; Raphyel Rosby; Patrick DiMario
Journal:  Nucleus       Date:  2014 Sep-Oct       Impact factor: 4.197

10.  Reconstitution of the human SRP system and quantitative and systematic analysis of its ribosome interactions.

Authors:  Klemens Wild; Keven D Juaire; Komal Soni; Vivekanandan Shanmuganathan; Astrid Hendricks; Bernd Segnitz; Roland Beckmann; Irmgard Sinning
Journal:  Nucleic Acids Res       Date:  2019-04-08       Impact factor: 16.971

View more
  2 in total

1.  Signal Recognition Particle in Human Diseases.

Authors:  Morgana K Kellogg; Elena B Tikhonova; Andrey L Karamyshev
Journal:  Front Genet       Date:  2022-06-08       Impact factor: 4.772

Review 2.  Targeting of Proteins for Translocation at the Endoplasmic Reticulum.

Authors:  Martin R Pool
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.